| Name | Argatroban |
| Description | Argatroban (MCI-9038), a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi. |
| In vitro | In a rat distal cerebral artery occlusion model, administration of Argatroban at a dose of 0.3 mg/hour significantly reduced the number of microthrombi following artery occlusion. Argatroban treatment (at 0.1 and 0.3 mg/hour) notably reversed the decline in local cerebral blood flow in rats with distal cerebral artery occlusion. |
| In vivo | Argatroban directly induces phenotypic transformation in vascular smooth muscle cells, upregulating the expression of myofilament-related proteins, PAI-1, and β-actin mRNA. In animal models with thrombosis rich in platelets and erythrocytes, Argatroban (ED50=125 μg/kg) demonstrates antithrombotic effects. It exhibits antithrombin activity across a range (Ki=5 nM-39 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 6 mg/mL (11.8 mM), Sonication is recommended.
DMSO : 45 mg/mL (88.47 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Thrombin | MD805 | MD 805 | MCI9038 | MCI 9038 | Inhibitor | inhibit | Argatroban |
| Inhibitors Related | Dabigatran Etexilate Mesylate | (S)-(+)-Ibuprofen | Edoxaban | AEBSF hydrochloride | Heparin sodium salt | Thrombin (MW 37kDa) | Edoxaban Tosylate Monohydrate | Menadione | Ozagrel | Avatrombopag | Eltrombopag Olamine | p-Hydroxycinnamic acid |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Bioactive Lipid Compound Library | Human Metabolite Library |
United States
